» Articles » PMID: 33568785

Metabolic Activation and Colitis Pathogenesis is Prevented by Lymphotoxin β Receptor Expression in Neutrophils

Abstract

Inflammatory bowel disease is characterized by an exacerbated intestinal immune response, but the critical mechanisms regulating immune activation remain incompletely understood. We previously reported that the TNF-superfamily molecule TNFSF14 (LIGHT) is required for preventing severe disease in mouse models of colitis. In addition, deletion of lymphotoxin beta receptor (LTβR), which binds LIGHT, also led to aggravated colitis pathogenesis. Here, we aimed to determine the cell type(s) requiring LTβR and the mechanism critical for exacerbation of colitis. Specific deletion of LTβR in neutrophils (LTβR), but not in several other cell types, was sufficient to induce aggravated colitis and colonic neutrophil accumulation. Mechanistically, RNA-Seq analysis revealed LIGHT-induced suppression of cellular metabolism, and mitochondrial function, that was dependent on LTβR. Functional studies confirmed increased mitochondrial mass and activity, associated with excessive mitochondrial ROS production and elevated glycolysis at steady-state and during colitis. Targeting these metabolic changes rescued exacerbated disease severity. Our results demonstrate that LIGHT signals to LTβR on neutrophils to suppress metabolic activation and thereby prevents exacerbated immune pathogenesis during colitis.

Citing Articles

eQTL in diseased colon tissue identifies novel target genes associated with IBD.

Nishiyama N, Silverstein S, Darlington K, Kennedy Ng M, Clough K, Bauer M bioRxiv. 2024; .

PMID: 39464142 PMC: 11507739. DOI: 10.1101/2024.10.14.618229.


Linoleoyl-lysophosphatidylcholine suppresses immune-related adverse events due to immune checkpoint blockade.

Mathews I, Saminathan P, Henglin M, Liu M, Nadig N, Fang C medRxiv. 2024; .

PMID: 39148854 PMC: 11326322. DOI: 10.1101/2024.08.07.24310974.


LTβR-RelB signaling in intestinal epithelial cells protects from chemotherapy-induced mucosal damage.

Chen Q, Munoz A, Korchagina A, Shou Y, Vallecer J, Todd A Front Immunol. 2024; 15:1388496.

PMID: 38873613 PMC: 11169669. DOI: 10.3389/fimmu.2024.1388496.


Role of Mitochondria in Inflammatory Bowel Diseases: A Systematic Review.

Sanchez-Quintero M, Rodriguez-Diaz C, Rodriguez-Gonzalez F, Fernandez-Castaner A, Garcia-Fuentes E, Lopez-Gomez C Int J Mol Sci. 2023; 24(23).

PMID: 38069446 PMC: 10707203. DOI: 10.3390/ijms242317124.


Exploring the glycolytic cross-talk genes between inflammatory bowel disease and colorectal cancer.

Ye C, Huang Y, Gao Y, Zhu S, Yuan J Funct Integr Genomics. 2023; 23(3):230.

PMID: 37428395 PMC: 10333365. DOI: 10.1007/s10142-023-01170-5.


References
1.
Kaplan G, Ng S . Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology. 2016; 152(2):313-321.e2. DOI: 10.1053/j.gastro.2016.10.020. View

2.
Abraham C, Cho J . Inflammatory bowel disease. N Engl J Med. 2009; 361(21):2066-78. PMC: 3491806. DOI: 10.1056/NEJMra0804647. View

3.
Roda G, Jharap B, Neeraj N, Colombel J . Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016; 7:e135. PMC: 4737871. DOI: 10.1038/ctg.2015.63. View

4.
Neurath M . Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017; 14(5):269-278. DOI: 10.1038/nrgastro.2016.208. View

5.
Sedy J, Bekiaris V, Ware C . Tumor necrosis factor superfamily in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2014; 7(4):a016279. PMC: 4382740. DOI: 10.1101/cshperspect.a016279. View